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Summary Tumour samples from 150 patients with squamous cell carcinoma of the oesophagus were
investigated immunohistochemically with the monoclonal antibody MIB-I, which recognises proliferating cells.
Using light microscopy, the number of MIB-I-positive tumour cells was counted in the areas with the highest
proliferative activity. The MIB-1 index was determined as the proportion of MIB-I-positive and MIB-1-
negative tumour cells. A considerable variation of the MIB-1 indices was found between the different tumours
with a minimum of 6% and a maximum of 95% (median, 33%). The MIB-1 index correlated significantly with
the mitotic activity in the tumour tissue (r=0.33; P=0.0001) and with the proportion ofapoptotic tumour cells
(r=0.25; P=0.0017). No significant correlation was found between the MIB-1 index and various other
prognostic parameters including pT classification, pN classification, tumour size, tumour grade, blood vessel
invasion and lymphatic vessel invasion. In the univariate survival analysis no significant difference was found
between tumours with low (<33%) and high MIB-1 index (>33%) (5-year survival rate: low MIB-1 index,
19.2%; high MIB-1 index, 22.2%). In a Cox proportional hazard regression analysis only the parameters
lymphatic vessel invasion (P=0.0001), pT classification (P=0.0034) and pN classification (P=0.0256), but not
the MIB-1 index, could be verified as independent prognostic variables. In conclusion, evaluation of the MIB-1
index does not provide prognostic information for oesophageal cancer patients.
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The stage of tumour growth, as defined by the TNM
classification (UICC, 1992), is the accepted basis for
predicting the prognosis of cancer patients. Nevertheless,
efforts have been made to define new prognostic parameters
which might improve accuracy in the prediction of patients'
outcome. In this context, the measurement of the tumour
growth fraction offers a potentially valuable approach for
predicting the clinical course and the response to therapy in
patients with cancer (Tannock, 1987). Thus, in breast cancer
(Gasparini et al., 1992; Clayton, 1991), in non-Hodgkin's
lymphoma (Hall et al., 1988) and soft-tissue sarcomas
(Trojani et al., 1984) the proliferative activity of the tumour
tissue is regarded as a prognostic factor independent of
known clinicopathological indicators.
One of the methods most frequently used to determine the
proportion of proliferating cells in malignant tumours is the
immunohistochemical detection of the nuclear Ki-67 antigen,
which is only expressed in proliferating, but not in resting
cells (Gerdes et al., 1984). A good correlation has been shown
between the immunohistochemical labelling of cell nuclei with
Ki-67 and other methods of assessing cell proliferation, e.g.
mitosis counts (Weidner et al., 1994), bromodeoxyuridine
labelling (Yonemura et al., 1990), flow cytometry (Walker et
al., 1988), thymidine labelling (Kamel et al., 1989) and
autoradiography (Gerdes et al., 1984). Recently, the
requirement of frozen sections for Ki-67 immunohistochem-
istry has been overcome by the generation of the monoclonal
MIB-1 antibody, which recognises a fixation-resistant epitope
of the Ki-67 antigen (Cattoretti et al., 1992). This provides
the opportunity to test the prognostic significance of tumour
cell proliferation on large retrospective series of different
types of human cancer.
Only a few studies are available concerning the prolif-
erative activity of squamous cell carcinomas of the
oesophagus (SCC). Thus Hippelainen et al. (1993), who
studied 61 SCCs, found no association between mitotic
activity and outcome of oesophageal cancer patients.
Porschen et al. (1991), who analysed the Ki-67 expression
in 27 oesophageal squamous cell carcinomas, found no
correlation between proliferative activity, TNM stage or
tumour grade. In the study of Youssef et al. (1995}, who
investigated MIB-1 expression in 72 samples of oesophageal
cancer, high MIB-1 indices were significantly correlated with
poor outcome according to the univariate survival analysis.
However, in this study no multivariate survival analysis was
performed to determine whether the MIB-1 index may be an
independent prognostic parameter.
Given the impression of these few and inconclusive results,
the present study was undertaken to investigate the possible
prognostic significance of tumour cell proliferation as
determined by the MIB-1 antibody in a series of 150
oesophageal cancer patients who underwent potential
curative resection therapy. The question to be followed up
was whether in oesophageal cancer, as in some other tumour
types, rapidly proliferating carcinomas display a more
unfavourable outcome than slowly proliferating carcinomas.
Materials and methods
Patients
The study comprised 150 patients who underwent potentially
curative resection for squamous cell carcinoma (SCC) of the
oesophagus from January 1978 to December 1992. Poten-
tially curative resection was defined as the absence of distant
metastases, the removal of all gross tumour and the
histologically confirmed absence of tumour tissue at the
surgical margins. No preoperative radio- or chemotherapy
was performed. Of the total 121 patients were male and 29
were female. The median age was 58 years (range 35-82
years). The follow-up ranged from 24 months to 192 months
after surgery (or to the date of death). Two patients were lost
to follow-up. Eighteen patients died of post-operative
complications (i.e. within 30 days), with 130 patients
remaining for the survival analyses.
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Pathological review
The surgical specimens from the primary tumours were fixed
in 4% buffered formalin, embedded in paraffin, and were
sectioned and stained with haematoxylin and eosin. An
average of 7 H and E-stained slides of tumour tissue was
available for the pathological review. The pT classification
and the pN classification were determined according to the
criteria proposed by the UICC (1992) and the grade of
tumour differentiation was determined according to the
criteria proposed by the World Health Organization (1990).
Tumour size was defined as the largest diameter of the
tumour. Accordingly, 25 tumours were categorised as pTl
(16.7%), 26 as pT2 (17.3%), 94 as pT3 (62.7%) and five as
pT4 (3.3%). Likewise, 72 cases were categorised as pNO
(48.0%) and 78 as pNI (52.0%). A total of 99 tumours had a
maximum diameter of 5 cm or less (66.0%), 51 tumours were
larger than 5 cm (34.0%). Eighteen tumours were graded as
GI (12.0%), 64 as G2 (42.7%), 60 as G3 (40.0%) and eight
as G4 (5.3%).
Additionally, the histological review included the para-
meters, lymphatic vessel invasion and blood vessel invasion.
Briefly, blood vessel invasion was regarded as definite when
tumour cells were found in an endothelium-lined vascular
space with a definite smooth muscle layer. Lymphatic vessel
invasion was regarded as definite when tumour cells were
detected in a thin-walled endothelium-lined space containing
no red blood cells. Accordingly, evidence of blood vessel
invasion was found in 37 tumours (24.7%) and lymphatic
vessel invasion was found in 54 tumours (36.0%).
Assessment of mitotic and apoptotic indices
For each case, one representative H and E-stained slide of
tumour tissue was selected for the assessment of the mitotic
index and the apoptotic index. These slides included central
and peripheral portions of the tumours. In the case of small
carcinomas, full cross-section tumour samples were used.
Mitotic and apoptotic tumour cells were counted in ten
randomly selected microscopic fields (corresponding to a total
of at least 1000 tumour cells), by using a quadratic reticle
with 25 squares of 4 mm2 inserted in a x 10 ocular lens (Del
Vecchio et al., 1991). For the random selection of
microscopic fields, each sample was initially examined at
low-power magnification ( x 4 objective lens and x 10 ocular
lens) in order to exclude areas of ulceration and necrosis.
Subsequently, mitotic figures and apoptotic bodies were
counted in ten microscopic fields under high-power
magnification ( x 40 objective lens and x 10 ocular lens),
starting in the centre of the tumour and subsequently shifting
into different parts of the tumour, without taking account of
tumour differentiation and proliferative activity. Apoptotic
cells were identified by cell shrinkage, with condensed
chromatin, and often deeply eosinophilic cytoplasm (Staun-
ton and Gaffney, 1995). Mitotic figures were separated from
apoptotic cells according to the following criteria (Baak,
1990): (1) absence of nuclear membrane; (2) absence of clear
zone in centre; (3) presence of hairy instead of triangular or
spiky projections; and (4) basophilia of surrounding
cytoplasm instead of eosinophilia. The mitotic index (MI)
and apoptotic index (Al) per case were expressed as
percentages, i.e. as the mean number of mitotic figures or
apoptotic bodies per 100 intact tumour cells.
Accordingly, the median MI was 0.8 (mean 0.8; range
0.1-3.1) and the median Al was 0.9 (mean 1.0; range 0.1-
3.8).
Assessment ofproliferative activity by MIB-1 staining
Consecutive sections from the paraffin blocks used for the
assessment of mitotic and apoptotic indices were stained with
the monoclonal antibody MIB-1 (Dianova, Hamburg,
Germany), which recognises a fixation-resistant epitope of
the Ki-67 antigen (Cattoretti et al., 1992). Sections were
placed on slides coated with 3-aminopropyltriethoxy-silane
(Sigma, Deisenhofen, Germany). After microwave pretreat-
ment in citrate buffer (pH 6.0) three times for 5 min at
750 W, the slides were stained using the avidin-biotin
complex technique (Hsu et al., 1981). The primary antibody
was diluted 1:10 with phosphate-buffered saline (PBS). The
slides were finally counterstained with haemalaune. Tonsils
were used as positive controls and negative controls were
performed by replacing the primary antibody with PBS. The
number of MIB-1-positive tumour cell nuclei and the total
number of tumour cell nuclei were counted by light
microscopy, again using a quadratic reticle with 25 squares
of 4 mm2 inserted in a x 10 ocular combined with a x 40
objective. A minimum of 1000 nuclei per tumour was counted
in the areas of the highest proliferative activity (Weidner et
al., 1994). The MIB-1 index was defined as the number of
tumour cells with positive nuclear immunostaining divided by
the total number of tumour cells counted per section.
Statistical analysis
Statistical analysis of the correlation between the MIB-1
index and other prognostic parameters was performed by
means of the Spearman rank correlation test for continuous
variables and by Student's t-test for categorical variables.
Survival rates were calculated by the Kaplan-Meier method
for analysis of censored data. The statistical significance of
differences in survival was analysed by means of the log-rank
test. The prognostic significance of parameters in multi-
parametric analyses was determined by means of a stepwise
forward Cox regression analysis. The parameters that were
not dichotomic were dichotomised for the multivariate
analysis as follows: pT classification (pTl/pT2 vs pT3/pT4),
age ( <55 years vs >55 years), tumour size ( 5 cm vs
>5 cm) and grading (G1/G2 vs G3/G4). P-values lower than
0.05 were considered as being significant.
Results
MIB-1-positive tumour cells were clearly identified by their
brown nuclear staining (Figure 1). In normal oesophageal
mucosa adjacent to the tumour tissue the MIB-1 expression
was always confined to the basal cell layer.
The proportion of MIB-1-positive tumour cells varied
widely between the different tumours. Thus, the minimum
MIB-1 index was 6% and the maximum MIB-l index was
95% (median 33%; mean+s.d. 41.5%+24.2; Figure 2).
Moreover, a heterogeneous intratumoral distribution of
MIB-1-positive tumour cells was found in many tumours.
In general, the highest proportion of MIB-1-positive tumour
cells was found at the tumour margins.
Correlation between mitotic index (MI), apoptotic index (AI)
and MIB-J index
The proportion of MIB-1-positive tumour cells ran parallel
with- MI and Al in the tumour tissue, showing higher
proportions of mitotic and apoptotic tumour cells in cases
with high MIB-1 indices than in cases with low MIB-1
indices. According to the Spearman rank correlation test,
there was a closer association between mitotic activity and
MIB-1 expression (r=0.33; P=0.0001) than between the
number of apoptotic tumour cells and MIB-1 expression
(r=0.25; P=0.0017).
Correlation between MIB-1 index and other prognostic
parameters (Table I)
There was a tendency for higher MIB-1 indices to occur in
poorly differentiated tumours than in highly differentiated
tumours. The mean MIB-1 index increased continuously
from 36.7% in GI carcinomas to 48.9% in G4 carcinomas.
However, this correlation failed to achieve statistical
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Table I Proliferative activity (proportion of MIB-1-positive tumour
cells) in 150 SCC of the oesophagus in relation to other prognostic
parameters (t-test)
Parameter
pT classification
pTl
pT2
pT3
pT4
pN classification
pNO
pNl
Tumour size
,<5 cm
>5 cm
Tumour grade
GI
G2
G3
G4
Blood vessel invasion
Absent
Present
Lymphatic vessel invasion
Absent
Present
s.d., standard deviation;
MIB-1
n (0)
25
26
94
5
36.6 (24.9)
45.6 (22.2)
42.2 (24.2)
32.4 (33.3)
72 41.4 (24.8)
78 41.6 (23.9)
99 42.9 (24.2)
51 38.8 (24.4)
18
64
60
8
36.7 (23.8)
39.6 (23.5)
44.1 (25.0)
48.9 (25.9)
113 41.4 (23.8)
37 41.9 (25.9)
96 42.6
54 39.6
NS, not significant.
Figure 1 Nuclear MIB-1 immunoreactivity in a moderately
differentiated squamous cell carcinoma of the oesophagus.
Original magnification x 300. Bar=50/,um.
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Figure 2 Histogram of the MIB-1 indices in 150 squamous cell
carcinomas of oesophagus.
significance. No correlation was found between the MIB-1
index and the parameters pT classification, pN classification,
tumour size, blood vessel invasion and lymphatic vessel
invasion.
Survival analysis (Table II)
For survival analysis the patients were stratified by the
median MIB-1 index into a group of patients with rapidly
proliferating tumours (MIB-1 index >33%) and a group of
patients with slowly proliferating tumours (MIB-1 index
.33%). No differences in survival were found between these
two groups of patients. Owing to the fact that there was a
relative maximum of tumours with 40% or less of MIB-1-
positive tumour cells (Figure 2), we additionally evaluated the
Table II Survival rates (%) of patients with SCC of the oesophagus
in relation to the proliferative activity (proportion of MIB-1-positive
tumour cells) using log-rank test
2-Year 5-Year
Patients (n) (s.e.) (s.e.) P-value
All carcinomas 0.843
<33% 65 41.5 (±6.1) 19.2 (±5.9)
>33% 65 38.5 (±6.0) 22.2 (±5.5)
Lymph node-negative 0.859
carcinomas
,<33% 30 66.7 (+8.6) 21.4 (±11.9)
>33% 30 53.3 (+8.9) 40.6 (±9.1)
Lymph node-positive 0.908
carcinomas
,<33% 36 19.4 (±6.6) 11.1 (±5.2)
>33% 34 26.5 (±7.6) 10.3 (±5.5)
s.e., standard error; NS, not significant.
40% level as a cut-off point for differentiating between slowly
proliferating and rapidly proliferating tumours. However, in
this analysis too, no significant differences in survival were
found (2 year survival rate/ 5 year survival rate-MIB- index
.40%: 40.9%/ 18.6%; MIB-1 index >40%: 37.5%/ 24.5%;
P=0.9810). Moreover, no significant differences in survival
were found when the patients were stratified by the 10
percentile, 30 percentile, 70 percentile or 90 percentile of
MIB-1 indices respectively (data not shown). Finally, no
significant differences in survival were found when the
prognostic influence of the MIB-1 index was investigated
separately either in lymph node-negative or lymph node-
positive carcinomas.
In a forward multivariate Cox regression analysis,
including the parameters pT classification, pN classification,
tumour grade, MIB-1 index, age, sex, tumour size, lymphatic
vessel invasion and blood vessel invasion, only the
parameters lymphatic vessel invasion (P=0.0001), pT
classification (P=0.0034) and pN classification (P=0.0256),
but not the MIB-1 index, could be verified as independent
prognostic variables.
(s.d.) P-value
NS
NS
NS
NS
NS
NS
(25.3)
(22.4)
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Discussion
The current study shows that the proportion of MIB-1-
expressing tumour cells in oesophageal cancer is not
correlated to prognostic parameters such as pT classifica-
tion, pN classification and tumour size. Moreover, the MIB-1
index has no impact on the outcome of oesophageal cancer
patients.
The MIB-1 indices obtained in our study are in line with
the results of earlier studies that had used the Ki-67 antibody
(Porschen et al., 1991) and the MIB-1 antibody (Youssef et
al., 1995) on oesophageal carcinomas. Thus, the mean Ki-67
index in the study of Porschen et al. (1991) (35.7%) and the
cut-off value to define low and high MIB-1 indices (mean or
median were not given) in the study of Youssef et al. (1995)
(30%) are very close to the median (33%) found in our study.
Furthermore, we found a reasonable correlation between
mitotic activity and MIB-1 immunoreactivity in our tumour
material. Thus, it can be concluded that the immunohisto-
chemical evaluation of formalin-fixed tumour samples using
the MIB-1 antibody gives a reliable estimation of the
proportion of proliferating tumour cells in oesophageal
cancer specimens.
The rate at which a tumour proliferates is traditionally
considered to bear a relationship to its clinical course. The
simplest and most established method for determining the
proliferative activity of a tumour is the counting of mitotic
figures. However, mitotic counts are not completely reliable
or reproducible (Quinn and Wright, 1990). The use of the
MIB-1 antibody may be a valuable alternative that can easily
be applied by surgical pathologists. However, there is
controversy as to the prognostic value of Ki-67 or MIB-1
immunohistochemistry. Whereas in female breast cancer
evidence is increasing that Ki-67 or MIB-1 immunoreactivity
may be an independent prognostic parameter (Bouzubar et
al., 1989; Gasparini et al., 1992; Railo et al., 1993), in various
other types of human cancer the situation is inconclusive and
occasionally contradictory. In colorectal cancer, for example,
Al-Sheneber et al. (1993) and Mayer et al. (1993) found a
significant correlation between proliferative activity and
outcome, whereas Kubota et al. (1992) did not find any
prognostic significance of tumour cell proliferation. With
regard to the prognostic significance of the MIB-1 index in
patients with SCC of the oesophagus, our results clearly
contradict the recently published study of Youssef et al.
(1995). According to the univariate survival analysis in that
study, comprising 70 cases of oesophageal squamous cell
carcinoma, tumours with low MIB-1 indices were associated
with a significantly better prognosis than tumours with high
MIB-1 indices, whereas we did not find such a correlation in
our series of oesophageal SCC patients. The reasons for such
differing results are difficult to assess; however, a rather
conspicious feature of the series of Youssef et al. (1995) is
that tumour stage was not a significant prognostic factor.
Since the stage of tumour growth is generally accepted to be
the most significant single prognostic factor in oesophageal
cancer (Jizuka et al., 1989; Kato et al., 1993), a bias in the
random collection of patients in the series of Youssef et al.
(1995) cannot be excluded. Hence, additional, more extensive
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